NIPT for fetal sexing (X-linked disorders)
NIPT for fetal sexing (X-linked disorders) (plasma).
Overview
The scheme is designed to assess the analytical process (genotyping), and reporting
(biological and clinical interpretation of the test result) including the
overall report layout, content and clerical accuracy.
At a glance
Product Code:
04-NIPT-FSEX-27
Target/Genes:
NIPT for the fetal sex determination in the context of X-linked disorders, which often require testing at an early gestational age.
Technology:
NIPT
Sample Type:
Plasma (cfDNA)
Submit Results In:
English, French, German, Italian, Spanish
Accredited:
Yes
Key Dates
01/03/2027
Oct-27
October- November 2027
March 2028
Sample Details
Two mock clinical cases with matching samples will be
provided. Approximately 1ml of artificial plasma containing approximately 30ng
DNA per sample is provided. Complete information will be available in the
scheme instructions.
EQA Results
Participants will receive an individual report including educational advice and a scheme report which includes additional information from the cohort of participants including geographical spread, methodologies employed, common errors, learning points and scheme statistics allowing participants to benchmark their results. Each laboratory will also receive a single certificate listing all EQAs participated in with performance result for each year.
Participation Information
Participants are expected to test samples according to their routine strategy and to return a clinical report.
No restrictions on number of participants. Open to laboratories from ALL countries (note: some restrictions may apply due to sanctions, delivery network exceptions, restrictions on importation etc).
This EQA is delivered in collaboration with GenQA.
Send your enquiry by submitting the form
Closes in 112 days
From £656.00
Buying is completed on the EMQN portal and needs a free EMQN account, which takes a few minutes to set up.
- ISO 17043 accredited scheme
- Submit results in 5 languages
Questions about this scheme?
Contact our team
Register Interest
Express your interest in ''.